Vitamariel® - Mother

Dosage form Application area Recommendations for use Contraindications Manufacturer
Read on
Certificate number:RU.77.99.11.003.Е.002908.06.17
Date of registration and renewal:29.06.2017
Dosage form: & nbspTablets weighing 0.8 g ± 15%.
Classification "Composition" & nbsp BAD - vitamin and mineral complexes Food supplements - carbohydrates and products of their processing
Classification "Clinical" & nbsp BAD-sources of multivitamins containing individual minerals and mineral complexes BAD-sources of vitamin-mineral complexes
Composition: & nbspSugar, calcium carbonate, ascorbic acid, iron fumarate, magnesium oxide, nicotinamide, vitamin E-acetate, E1201, titanium dioxide, zinc oxide, stearic acid, calcium pantothenate, aerosil, pyridoxine hydrochloride, thiamine hydrochloride, retinol acetate, folic acid, talcum , beeswax, vaseline oil, cholecalciferol, cyanocobolamine, potassium iodide, sodium molybdate, sodium selenite, chromium chloride, manganese sulfate, riboflavin, E460, E122.
Scope: & nbspFor realization to the population as a biologically active additive to food - an additional source of vitamins and minerals for women during pregnancy and in the postpartum period.
Suggested Usage: & nbspWomen in the planning stage of pregnancy, during pregnancy and in the postpartum period, regardless of whether they are breastfed or not - 1 tablet a day during meals. Duration of admission is 1 month.
Contraindications:Individual intolerance of components, simultaneous reception with drugs containing vitamins A and D, hypercalcemia,impaired renal function.
Special instructions:Before use, it is recommended to consult a doctor.
Shelf life:24 months.
Storage conditions:Store in a dry place inaccessible to children at a temperature not exceeding 25 ° C.
Research protocols:In exchange for the certificate of state registration No. RU.77.99.11.003.Е.001102.03.17 of 06/03/2017, the expert opinion of the FGBUN "NII Nutrition" №72 / Э-1292 / б-15 of 17.09.2015, the test report IL FGBU "Information and Methodological Center for Expertise, Accounting and Analysis of Treatment of Medical Use" No. 544DK-08/16 of December 27, 2016.
Recipient:Marbiopharm, OJSCMarbiopharm, OJSC Russia
Information update date: & nbsp07.09.2017
Instructions
Up